Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR)

被引:45
作者
Beaufort, N
Debela, M
Creutzburg, S
Kellermann, J
Bode, W
Schmitt, M
Pidard, D
Magdolen, V [1 ]
机构
[1] Tech Univ Munich, Klin Forschergruppe Frauenklin, D-81675 Munich, Germany
[2] Inst Pasteur, INSERM, Unite Defense Innee & Inflammat, E0336,Dept Mol Med, F-75015 Paris, France
[3] Max Planck Inst Biochem, Abt Strukturforschung, D-82152 Martinsried, Germany
[4] Max Planck Inst Biochem, Abt Proteinanaly, D-82152 Martinsried, Germany
关键词
enamel matrix serine protease 1; invasion; metastasis; prostase; tumor-associated proteolytic system;
D O I
10.1515/BC.2006.029
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The plasminogen activation system is involved in cancer progression and metastasis. Among other proteolytic factors, it includes the serine protease urokinase-type plasminogen activator (uPA) and its three-domain (D1D2D3) receptor uPAR (CD87), which focuses plasminogen activation to the cell surface. The function of uPAR is regulated in part through shedding of domain D1 by proteases, e. g., uPA itself or plasmin. Human tissue kallikrein 4 (hK4), which is highly expressed in prostate and ovarian tumor tissue, was previously shown to cleave and activate the pro-enzyme forms of prostate-specific antigen (PSA, tissue kallikrein hK3) and uPA. Here we demonstrate that uPAR is also a target for hK4, being cleaved in the D1-D2 linker sequence and, to a lesser extent, in its D3 juxtamembrane domain. hK4 may thus modulate the tumor-associated uPA/uPAR-system activity by either activating the pro-enzyme form of uPA or cleaving the cell surface-associated uPA receptor.
引用
收藏
页码:217 / 222
页数:6
相关论文
共 32 条
  • [1] Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue
    Almasi, CE
    Hoyer-Hansen, G
    Christensen, IJ
    Dano, K
    Pappot, H
    [J]. LUNG CANCER, 2005, 48 (03) : 349 - 355
  • [2] Andolfo A, 2002, THROMB HAEMOSTASIS, V88, P298
  • [3] Plasmin cleaves the juxtamembrane domain and releases truncated species of the urokinase receptor (CD87) from human bronchial epithelial cells
    Beaufort, N
    Leduc, D
    Rousselle, JC
    Namane, A
    Chignard, M
    Pidard, D
    [J]. FEBS LETTERS, 2004, 574 (1-3) : 89 - 94
  • [4] Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G
    Beaufort, N
    Leduc, D
    Rousselle, JC
    Magdolen, V
    Luther, T
    Namane, A
    Chignard, M
    Pidard, D
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 172 (01) : 540 - 549
  • [5] uPAR: A versatile signalling orchestrator
    Blasi, F
    Carmeliet, P
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2002, 3 (12) : 932 - 943
  • [6] The emerging roles of human tissue kallikreins in cancer
    Borgoño, CA
    Diamandis, EP
    [J]. NATURE REVIEWS CANCER, 2004, 4 (11) : 876 - 890
  • [7] The tissue kallikrein family of serine proteases: Functional roles in human disease and potential as clinical
    Clements, JA
    Willemsen, NM
    Myers, SA
    Dong, Y
    [J]. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2004, 41 (03) : 265 - 312
  • [8] Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer
    de Bock, CE
    Wang, Y
    [J]. MEDICINAL RESEARCH REVIEWS, 2004, 24 (01) : 13 - 39
  • [9] Dong Y, 2001, CLIN CANCER RES, V7, P2363
  • [10] A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity
    Fazioli, F
    Resnati, M
    Sidenius, N
    Higashimoto, Y
    Appella, E
    Blasi, F
    [J]. EMBO JOURNAL, 1997, 16 (24) : 7279 - 7286